Senior Officer, Drug Discovery at Gates Foundation

Job description

The Foundation We are the largest nonprofit fighting poverty, disease, and inequity around the world. Founded on a simple premise: people everywhere, regardless of identity or circumstances, should have the chance to live healthy, productive lives. We believe our employees should reflect the rich diversity of the global populations we aim to serve. We provide an exceptional benefits package to employees and their families which include comprehensive medical, dental, and vision coverage with no premiums, generous paid time off, paid family leave, foundation-paid retirement contribution, regional holidays, and opportunities to engage in several employee communities. As a workplace, we’re committed to creating an environment for you to thrive both personally and professionally. The Team Our Global Health (GH) program harnesses advances in science and technology to save lives in low and middle income countries. We focus on the health problems that have a major impact in developing countries but get too little attention and funding. Where proven tools exist, we support sustainable ways to improve their delivery. Where they don’t, we invest in research and development of new interventions, such as vaccines, drugs, and diagnostics. Our work in infectious diseases focuses on strategies to fight and prevent HIV/AIDS, malaria, tuberculosis, neglected and other infectious diseases, enteric and diarrheal diseases and pneumonia. These strategies are supported by functional teams that focus on Discovery and Translational Sciences, Vaccine Development, and Integrated Development. The Accelerator funds the creation of novel technology capabilities that enable the achievement of the foundation’s mission by fostering the conception, design, and testing of fundamentally new biotech platforms that have the potential to change current best practices or business models and show proof of concept for these platforms. By leveraging grants, equity, and donor capital, we work to ensure the capabilities advanced further the foundation’s objectives and support the transition of these new technology platforms to execution partners. Some platform capabilities that we are exploring include harnessing the power of chemo-sensing for ultra-high sensitivity detection of volatiles, programming immune system responses for design of next generation vaccine modalities, and engineering antibodies for oral delivery. Our team also includes more mature programmatic units aiming to achieve a “single-shot cure” for HIV and sickle cell disease in the next ten years, harness AI and machine learning tools to radically advance drug discovery and development to cure HPV and pre-eclampsia, and develop five new preclinical oral polio vaccine candidates in the next two years. The HIV Frontiers program is a high-priority initiative of the Gates Foundation within the Accelerator, a long-horizon effort to develop curative interventions for HIV disease and sickle cell disease: a single-shot, durable, safe, effective, and affordable “cure” (i.e., durable viral control in the absence of antiretroviral therapy in the case of HIV and durable resolution of anemia and painful crises in the case of SCD), one that can reach the populations most in need — especially those living in low- and middle-income countries (LMICs) in sub-Saharan Africa and South Asia, where both diseases carry their heaviest burden. The program currently funds a portfolio of multiple organizations — ranging from major pharmaceutical companies to early-stage NewCos — each receiving major equity and/or grant support from the Foundation. Grantees also include academic medical centers, contract development and manufacturing organizations (CDMOs), and international regulatory bodies. Work on these investments spans the full development continuum: from basic scientific input and target identification, through chemistry, manufacturing and controls (CMC), preclinical IND-enabling studies, and first-in-human (FIH) clinical tri